Project Grant F31CA281063
Award Date
9/28/24
Completion Date
6/30/26
Dollars Obligated
$154K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584 to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the genomic and transcriptomic underpinnings of metastatic spread in triple-negative breast cancer (TNBC). The award period is from April 1, 2025 to March 31, 2030. The research will focus on decoding the co-evolution of cancer subclones and their tumor microenvironment across...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $125,000 to Baylor College of Medicine for the project "Characterization of the Metastatic Time by Subcellular Spatial Profiling". The research aims to understand the role of macrophages and tumor-infiltrating lymphocytes in the tumor immune microenvironment of triple-negative breast cancer metastases. The project will utilize...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $571,496 Project Grant to the University of Toledo Health Science Campus Division to conduct research aimed at understanding the mechanisms by which the tumor-intrinsic TAZ expression regulates the tumor microenvironment and immune suppressive cells like myeloid-derived suppressor cells (MDSCs) in triple-negative breast cancer (TNBC). The research project, titled "Dissecting Molecular Mechanisms of Tumor-Induced...
This federal Project Grant award for $719,799, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to investigate the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The award to Health Research, Inc. aims to determine how the metabolic enzyme PFKFB4 drives TNBC progression and metastasis through intrinsic regulation of metabolic and genetic pathways, as well...
This $118,912 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to characterize and overcome major histocompatibility complex class I (MHC-I)-mediated immune evasion in triple-negative breast cancer (TNBC). The primary awardee, the University of North Carolina at Chapel Hill, will conduct experiments to determine how MHC-I loss affects tumor progression and immune cell infiltration, as well as evaluate combination...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant to The Johns Hopkins University to conduct research on comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The project, funded under CFDA 93.398 Cancer Research Manpower, aims to characterize differences in tumor-associated macrophage (TAM) functional attributes and their regulation between M-CSF and GM-CSF, as well as investigate...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $125,834 to Baylor College of Medicine to conduct research focused on the functional role of Wnt/Ca2+ signaling in triple-negative breast cancer (TNBC) metastasis and chemoresistance. The overarching goals are to establish a mouse model capable of measuring intracellular Ca2+ levels to unravel the Wnt/Ca2+ signaling pathway in TNBC, understand how this signaling modulates tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) totaling $619,764 aims to develop new combination immunotherapy strategies to enhance the anti-tumor efficacy against triple-negative breast cancer (TNBC). The award will fund research to: Increase tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor delivery system (P-aPDL1) by triggering local thrombus formation at the TNBC site using a truncated tissue...
This $400,000 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program aims to activate the transcription factor EB (TFEB) in order to enhance the efficacy of immunotherapy for triple-negative breast cancer (TNBC). The funded research will evaluate the toxicity and pharmacokinetic properties of the TFEB activator compound USCYL01, as well as test its ability to improve the efficacy of immune checkpoint inhibitor (ICI) therapy combined with...